DOI QR코드

DOI QR Code

Anticancer Activity of Acanthopanax trifoliatus (L) Merr Extracts is Associated with Inhibition of NF-κB Activity and Decreased Erk1/2 and Akt Phosphorylation

  • Wang, Hua-Qian (Allan H Conney Laboratory for Anticancer Research, School of Chemical Engineering and Light Industry, Guangdong University of Technology) ;
  • Li, Dong-Li (Allan H Conney Laboratory for Anticancer Research, School of Chemical Engineering and Light Industry, Guangdong University of Technology) ;
  • Lu, Yu-Jing (Allan H Conney Laboratory for Anticancer Research, School of Chemical Engineering and Light Industry, Guangdong University of Technology) ;
  • Cui, Xiao-Xing (Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy) ;
  • Zhou, Xiao-Fen (Allan H Conney Laboratory for Anticancer Research, School of Chemical Engineering and Light Industry, Guangdong University of Technology) ;
  • Lin, Wei-Ping (Allan H Conney Laboratory for Anticancer Research, School of Chemical Engineering and Light Industry, Guangdong University of Technology) ;
  • Conney, Allan H. (Allan H Conney Laboratory for Anticancer Research, School of Chemical Engineering and Light Industry, Guangdong University of Technology) ;
  • Zhang, Kun (Allan H Conney Laboratory for Anticancer Research, School of Chemical Engineering and Light Industry, Guangdong University of Technology) ;
  • Du, Zhi-Yun (Allan H Conney Laboratory for Anticancer Research, School of Chemical Engineering and Light Industry, Guangdong University of Technology) ;
  • Zheng, Xi (Allan H Conney Laboratory for Anticancer Research, School of Chemical Engineering and Light Industry, Guangdong University of Technology)
  • Published : 2014.11.28

Abstract

Acanthopanax trifoliatus (L) Merr (AT) is commonly used as an herbal medicine and edible plant in some areas of China and other Asian countries. AT is thought to have anticancer effects, but potential mechanisms remain unknown. To assess the anticancer properties of AT, we exposed prostate cancer cells to AT extracts and assessed cell proliferation and signaling pathways. An ethanol extract of AT was suspended in water followed by sequential extraction with petroleum ether, ethyl acetate and n-butanol. PC-3 cells were treated with different concentrations of each extract and cell viability was determined by the MTT and trypan blue exclusion assays. The ethyl acetate extract of the ethanol extract had a stronger inhibitory effect on growth and a stronger stimulatory effect on apoptosis than any of the other extracts. Mechanistic studies demonstrated that the ethyl acetate extract suppressed the transcriptional activity of NF-${\kappa}B$, increased the level of caspase-3, and decreased the levels of phospho-Erk1/2 and phospho-Akt. This is the first report on the anticancer activity of AT in cultured human prostate cancer cells. The results suggest that AT can provide a plant-based medicine for the treatment or prevention of prostate cancer.

Acknowledgement

Supported by : Guangdong Natural Science Foundation

References

  1. Wegiel B, Evans S, Hellsten R, et al (2010). Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Curr Cancer Drug Targets, 10, 392-401. https://doi.org/10.2174/156800910791208562
  2. Wei X, Du ZY, Cui XX, et al (2012). Effects of cyclohexanone analogues of curcumin on growth, apoptosis and NF-kappaB activity in PC-3 human prostate cancer cells. Oncol Lett, 4, 279-84.
  3. Ye Y, Hou R, Chen J, et al (2012). Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation. Horm Metab Res, 44, 263-7. https://doi.org/10.1055/s-0032-1301922
  4. Zheng X, Chang RL, Cui XX, et al (2008). Inhibition of NF-kappaB by (E)3-[ (4-methylphenyl)-sulfonyl]-2-propenenitrile (BAY11-7082; BAY) is associated with enhanced 12-O-tetradecanoylphorbol-13-acetate-induced growth suppression and apoptosis in human prostate cancer PC-3 cells. Int J Oncol, 32, 257-64.
  5. Zheng X, Chang RL, Cui XX, et al (2004). Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice. Cancer Res, 64, 1811-20. https://doi.org/10.1158/0008-5472.CAN-03-2848
  6. So A, Gleave M, Hurtado-Col A, et al (2005). Mechanisms of the development of androgen independence in prostate cancer. World J Urol, 23, 1-9. https://doi.org/10.1007/s00345-004-0473-1
  7. Uzgare AR, Isaacs JT (2005). Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways. Int J Biochem Cell Biol, 37, 707-14. https://doi.org/10.1016/j.biocel.2004.11.018
  8. Bhargavan B, Fatma N, Chhunchha B, et al (2012). LEDGF gene silencing impairs the tumorigenicity of prostate cancer DU145 cells by abating the expression of Hsp27 and activation of the Akt/ERK signaling pathway. Cell Death Dis, 3, 316. https://doi.org/10.1038/cddis.2012.57
  9. Chi KN, Bjartell A, Dearnaley D, et al (2009). Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol, 56, 594-605. https://doi.org/10.1016/j.eururo.2009.06.027
  10. Chi VV (1997). Vietnamese Medical Plant Dictionary. 622.
  11. Cragg GM, Newman DJ (2005). Plants as a source of anti-cancer agents. J Ethnopharmacol, 100, 72-9. https://doi.org/10.1016/j.jep.2005.05.011
  12. De Marzo AM, Platz EA, Sutcliffe S, et al (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer, 7, 256-69. https://doi.org/10.1038/nrc2090
  13. Gioeli D, Mandell JW, Petroni GR, et al (1999). Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res, 59, 279-84.
  14. Gomella LG, Johannes J, Trabulsi EJ (2009). Current prostate cancer treatments: effect on quality of life. Urology, 73, 28-35. https://doi.org/10.1016/j.urology.2009.03.003
  15. Antonarakis ES, Carducci MA, Eisenberger MA (2010). Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett, 291, 1-13. https://doi.org/10.1016/j.canlet.2009.08.012
  16. Baade PD, Youlden DR, Krnjacki LJ (2009). International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res, 53, 171-84. https://doi.org/10.1002/mnfr.200700511
  17. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74. https://doi.org/10.1016/j.cell.2011.02.013
  18. Hansson A, Marin YE, Suh J, et al (2005). Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-kappaB inhibitor. Int J Oncol, 27, 941-8.
  19. Hsu JC (1996). Multiple comparisons: theory and methods.
  20. Ianni M, Porcellini E, Carbone I, et al (2013). Genetic factors regulating inflammation and DNA methylation associated with prostate cancer. Prostate Cancer Prostatic Dis, 16, 56-61. https://doi.org/10.1038/pcan.2012.30
  21. Junttila MR, Li SP, Westermarck J (2008). Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J, 22, 954-65.
  22. Karin M (2009). NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol, 1, 000141. https://doi.org/10.1101/cshperspect.a000141
  23. Kaur P, Shukla S, Gupta S (2008). Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study. Carcinogenesis, 29, 2210-7. https://doi.org/10.1093/carcin/bgn201
  24. Kook SH, Jang YS, Lee JC (2011). Involvement of JNK-AP-1 and ERK-NF-kappaB signaling in tension-stimulated expression of type I collagen and MMP-1 in human periodontal ligament fibroblasts. J Appl Physiol, 111, 1575-83. https://doi.org/10.1152/japplphysiol.00348.2011
  25. Lessard L, Mes-Masson AM, Lamarre L, et al (2003). NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int, 91, 417-20. https://doi.org/10.1046/j.1464-410X.2003.04104.x
  26. Liu XH, Kirschenbaum A, Lu M, et al (2002). Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun, 290, 249-55. https://doi.org/10.1006/bbrc.2001.6188
  27. Loblaw DA, Virgo KS, Nam R, et al (2007). Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol, 25, 1596-605. https://doi.org/10.1200/JCO.2006.10.1949
  28. Loi DT (2000). Glossary of vietnamese medical plants. 379.
  29. Maeda S, Omata M (2008). Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci, 99, 836-42. https://doi.org/10.1111/j.1349-7006.2008.00763.x
  30. Meiyanto E, Hermawan A, Anindyajati (2012). Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev, 13, 427-36. https://doi.org/10.7314/APJCP.2012.13.2.427
  31. McCubrey JA, Steelman LS, Chappell WH, et al (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta, 1773, 1263-84. https://doi.org/10.1016/j.bbamcr.2006.10.001
  32. Neri B, Molinara E, Pantaleo P, et al (2009). Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma. Oncol Res, 17, 565-70. https://doi.org/10.3727/096504009789745539
  33. Paule B, Terry S, Kheuang L, et al (2007). The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol, 25, 477-89. https://doi.org/10.1007/s00345-007-0175-6
  34. Pilat MJ, Kamradt JM, Pienta KJ (1998). Hormone resistance in prostate cancer. Cancer Metastasis Rev, 17, 373-81. https://doi.org/10.1023/A:1006166511344
  35. Raman M, Chen W, Cobb MH (2007). Differential regulation and properties of MAPKs. Oncogene, 26, 3100-12. https://doi.org/10.1038/sj.onc.1210392
  36. Ross JS, Kallakury BV, Sheehan CE, et al (2004). Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res, 10, 2466-72. https://doi.org/10.1158/1078-0432.CCR-0543-3
  37. Sambantham S, Radha M, Paramasivam A, et al (2013). Molecular mechanism underlying hesperetin-induced apoptosis by in silico analysis and in prostate cancer PC-3 cells. Asian Pac J Cancer Prev, 14, 4347-52. https://doi.org/10.7314/APJCP.2013.14.7.4347
  38. Sarker D, Reid AH, Yap TA, et al (2009). Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res, 15, 4799-805. https://doi.org/10.1158/1078-0432.CCR-08-0125
  39. Saunders FR, Wallace HM (2010). On the natural chemoprevention of cancer. Plant Physiol Biochem, 48, 621-6. https://doi.org/10.1016/j.plaphy.2010.03.001
  40. Schroder FH (2008). Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol, 53, 1129-37. https://doi.org/10.1016/j.eururo.2008.01.049
  41. Shukla S, MacLennan GT, Fu P, et al (2004). Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia, 6, 390-400. https://doi.org/10.1593/neo.04112
  42. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138

Cited by

  1. Radical Intermediate Generation and Cell Cycle Arrest by an Aqueous Extract of Thunbergia Laurifolia Linn. in Human Breast Cancer Cells vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4357
  2. Inhibition of tumor necrosis factor-α enhances apoptosis induced by nuclear factor-κB inhibition in leukemia cells pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.3786